Neurology 2000;55:1748-1751
© 2000 American Academy of Neurology
A placebo-controlled crossover trial of creatine
in mitochondrial diseases
T. Klopstock, MD,
V. Querner, MD, F. Schmidt,
F. Gekeler, MD, M. Walter, MD,
M. Hartard, MD,
M. Hennig Dipl-Stat,
T. Gasser, MD, D. Pongratz, MD,
A. Straube, MD,
M. Dieterich, MD and
W. MŸllerÐFelber, MD
From the Department of Neurology (Drs.
Klopstock, Querner, Gekeler, Gasser, Straube, and Dieterich,
and F. Schmidt) and the Friedrich-Baur-Institut (Drs.
Walter, Pongratz, and MŸllerÐFelber),
Ludwig-Maximilians-UniversitSt MŸnchen; and the
Department of Sports Medicine (Dr. Hartard) and the
Institute for Medical Statistics and Epidemiology (M.
Hennig), Technische UniversitSt MŸnchen,
Germany.
Address correspondence and reprint
requests to Dr. Thomas Klopstock, Department of Neurology,
Klinikum Grosshadern, Ludwig-Maximilians-UniversitSt
MŸnchen, D-81366 MŸnchen, Germany; e-mail:
klopstock@brain.nefo.med.uni-muenchen.de
To test the efficacy and safety of
creatine (Cr) monohydrate in mitochondrial diseases, 16
patients with chronic progressive external ophthalmoplegia
or mitochondrial myopathy were randomized in a crossover
design to receive double-blind placebo or 20 g Cr/day for 4
weeks. Cr was well tolerated, but there were no significant
effects with regard to exercise performance, eye movements,
or activities of daily life. The power of this pilot study
was limited and future multicenter trials are
needed.
Copyright © 2000 by AAN Enterprises,
Inc.
Full text of article may be obtained, not
free, at http://www.neurology.org/cgi/content/full/55/11/1748
|
